AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Delcath Systems Inc. (DCTH)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

15.55

-0.18 (-1.14%)

At close: Feb 20, 2025, 3:59 PM

15.54

-0.06%

After-hours: Feb 20, 2025, 04:35 PM EST

undefined% (undefined)

Bid	15.54
Market Cap	497.19M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.17
PE Ratio (ttm)	-13.29
Forward PE	n/a
Analyst	Buy

Ask	16.3
Volume	232,484
Avg. Volume (20D)	400,825
Open	15.53
Previous Close	15.73
Day's Range	15.24 - 15.69
52-Week Range	3.70 - 16.97
Beta	undefined

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial fo...

[Show more]

Industry Medical - Specialties

Sector Healthcare

IPO Date May 3, 2018

Employees 76

Stock Exchange NASDAQ

Ticker Symbol DCTH

Website https://www.delcath.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is $21.5, which is an increase of 38.26% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Delcath Systems Inc. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+11.41%

Delcath Systems shares are trading higher after th... Unlock content with Pro Subscription

4 months ago

+7.57%

Delcath Systems shares are trading higher after the company announced better-than-expected preliminary Q3 revenue results.

News

6 days ago · businesswire.com

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

1 week ago · zacks.com

Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 weeks ago · zacks.com

Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, th...

3 weeks ago · youtube.com

Biotech walks a 'tightrope' amid unclear funding, regulations

Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se...

3 weeks ago · zacks.com

Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable

Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 month ago · zacks.com

Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why

Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 month ago · businesswire.com

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

1 month ago · businesswire.com

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

2 months ago · businesswire.com

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U...

3 months ago · seekingalpha.com

Delcath Begins Platform Expansion With Two Phase 2 Trials

Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing...